Sophie Olivier

Sophie Olivier

Company: Atamyo Therapeutics

Job title: Chief Medical Officer


Design & Rationale of the ATA-001-FKRP Gene Therapy Study in Fukutin- Related Protein Limb-Girdle Muscular Dystrophy (LGMDR9) Patients 12:00 pm

Atamyo’s trial uses an optimized gene therapy construct, ATA-100, a recombinant viral vector composed of the viral capsid of the adeno-associated virus serotype 9 (AAV9) and a codon-optimized complementary DNA (cDNA) sequence encoding the human FKRP under the transcriptional control of a human muscle-specific promoter Safety, tolerability, effect on muscular, cardiac, and quality of life…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.